Inken Hilgendorf1, Hildegard Greinix, Jörg P Halter, Anita Lawitschka, Hartmut Bertz, Daniel Wolff. 1. Clinic of Internal Medicine II, University Hospital Jena, University Clinic of Internal Medicine I, Medical University of Vienna, Austria, Department of Hematology, University Hospital of Basel, St. Anna Children's Hospital, Vienna, Austria, Department of Hematology, Oncology, and Stem-Cell Transplantation, Medical Center - University of Freiburg, Department of Internal Medicine III, University Hospital Regensburg.
Abstract
BACKGROUND: Over 3000 persons undergo allogeneic hematopoietic stem-cell transplantation (allo-HSCT) in Germany every year. Advances in allo-HSCT have prolonged the survival of treated patients but have concomitantly increased the risk of long-term complications that impair their quality of life. METHODS: This literature review of the long-term sequelae of allo-HSCT is based on pertinent articles that were retrieved by a selective search of PubMed, and on current international guidelines. Case reports were excluded from consideration. RESULTS: Hardly any randomized clinical trials have been performed to investigate the long-term outcome of allo-HSCT, but international consensus-based guidelines have been published. 50% to 70% of patients treated with allo-HSCT develop chronic graft-versus-host disease (cGVHD) within ten years of treatment. Transplant recipients are at higher risk of infection, including the reactivation of dormant herpes viruses; therefore, vaccination is recommended, as described in the current guidelines. Gonadal dysfunction arises in up to 92% of men and up to 99% of women; its frequency depends on the timing of transplantation, on radiotherapy, and on other factors. The medications that transplant recipients need to take can impair liver function, and transfusionassociated hemosiderosis can do so as well. 40% to 50% of patients suffer from lipid metabolic disturbances that increase the risk of myocardial infarction, peripheral arterial occlusive disease, and stroke. Their life expectancy is shorter than that of the overall population. CONCLUSION: Measures should be taken to prevent the potential long-term complications of allo-HSCT. All patients who have been treated with allo-HSCT should receive individualized, risk-adapted, and multidisciplinary follow-up care, so that any complications that arise can be correctly diagnosed and appropriately treated. Long-term follow-up care could be improved by prospective clinical trials investigating the long-term sequelae of allo-HSCT, as well as by consistent, uniform documentation of these sequelae in supraregional data registries.
BACKGROUND: Over 3000 persons undergo allogeneic hematopoietic stem-cell transplantation (allo-HSCT) in Germany every year. Advances in allo-HSCT have prolonged the survival of treated patients but have concomitantly increased the risk of long-term complications that impair their quality of life. METHODS: This literature review of the long-term sequelae of allo-HSCT is based on pertinent articles that were retrieved by a selective search of PubMed, and on current international guidelines. Case reports were excluded from consideration. RESULTS: Hardly any randomized clinical trials have been performed to investigate the long-term outcome of allo-HSCT, but international consensus-based guidelines have been published. 50% to 70% of patients treated with allo-HSCT develop chronic graft-versus-host disease (cGVHD) within ten years of treatment. Transplant recipients are at higher risk of infection, including the reactivation of dormant herpes viruses; therefore, vaccination is recommended, as described in the current guidelines. Gonadal dysfunction arises in up to 92% of men and up to 99% of women; its frequency depends on the timing of transplantation, on radiotherapy, and on other factors. The medications that transplant recipients need to take can impair liver function, and transfusionassociated hemosiderosis can do so as well. 40% to 50% of patients suffer from lipid metabolic disturbances that increase the risk of myocardial infarction, peripheral arterial occlusive disease, and stroke. Their life expectancy is shorter than that of the overall population. CONCLUSION: Measures should be taken to prevent the potential long-term complications of allo-HSCT. All patients who have been treated with allo-HSCT should receive individualized, risk-adapted, and multidisciplinary follow-up care, so that any complications that arise can be correctly diagnosed and appropriately treated. Long-term follow-up care could be improved by prospective clinical trials investigating the long-term sequelae of allo-HSCT, as well as by consistent, uniform documentation of these sequelae in supraregional data registries.
Authors: Joachim Wiskemann; Peter Dreger; Rainer Schwerdtfeger; Andrea Bondong; Gerhard Huber; Nikolaus Kleindienst; Cornelia M Ulrich; Martin Bohus Journal: Blood Date: 2010-12-29 Impact factor: 22.113
Authors: K Scott Baker; Smita Bhatia; Nancy Bunin; Michael Nieder; Christopher C Dvorak; Lillian Sung; Jean E Sanders; Joanne Kurtzberg; Michael A Pulsipher Journal: Biol Blood Marrow Transplant Date: 2011-06-30 Impact factor: 5.742
Authors: G Socié; J Y Cahn; J Carmelo; J P Vernant; J P Jouet; N Ifrah; N Milpied; M Michallet; B Lioure; J L Pico; F Witz; L Molina; A Fischer; V J Bardou; E Gluckman; J Reiffers Journal: Br J Haematol Date: 1997-06 Impact factor: 6.998
Authors: John R Wingard; Navneet S Majhail; Ruta Brazauskas; Zhiwei Wang; Kathleen A Sobocinski; David Jacobsohn; Mohamed L Sorror; Mary M Horowitz; Brian Bolwell; J Douglas Rizzo; Gérard Socié Journal: J Clin Oncol Date: 2011-04-04 Impact factor: 44.544
Authors: K Robien; L G Strayer; N Majhail; D Lazovich; K S Baker; A R Smith; D A Mulrooney; L J Burns Journal: Bone Marrow Transplant Date: 2011-01-17 Impact factor: 5.483
Authors: G C Hildebrandt; T Fazekas; A Lawitschka; H Bertz; H Greinix; J Halter; S Z Pavletic; E Holler; D Wolff Journal: Bone Marrow Transplant Date: 2011-03-28 Impact factor: 5.483
Authors: Nirali N Shah; Alexandra F Freeman; Helen Su; Kristen Cole; Mark Parta; Niki M Moutsopoulos; Safa Baris; Elif Karakoc-Aydiner; Thomas E Hughes; Heidi H Kong; Steve M Holland; Dennis D Hickstein Journal: Biol Blood Marrow Transplant Date: 2017-03-10 Impact factor: 5.742
Authors: Sydney Corey; Brooke Bonsack; Matt Heyck; Alex Shear; Nadia Sadanandan; Henry Zhang; Cesar V Borlongan Journal: Brain Hemorrhages Date: 2020-01-22